Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Isoniazid Metabolism
Homo sapiens
Metabolic Pathway
Isoniazid is an antibiotic drug used to treat tunerculosis, as well as other types of mycobacteria.
Through a currently unknown reaction that may be spontaneous or enzymatic, pyruvic acid or oxoglutaric acid can undergo a dehydration reaction with isoniazid, forming isoniazid pyruvate or isoniazid alpha-ketoglutaric acid. Isoniazid may also react with hydrogen peroxide in the lysosome, forming an isonicotinoyl radical catalyzed by myeloperoxidase. The isonicotinoyl radical can then have either NAD or NADP added in a non-enzymatic reaction, forming isonicotinoyl-NAD and NADP adducts.
Isoniazid can have an acetyl group added to it by arylamine N-acetyltransferase 2, fvorming acetylisoniazid. This can then enter the endoplasmic reticulum and, with the addition of a water molecule, can form isonicotinic acid and acetylhydrazine. Isoniazid can also be converted to hydrazine and isonicotinic acid via the same reaction, and the hydrazine can have an acetyl group added to it by arylamine N-acetyltransferase 2 in order to form acetylhydrazine. Acetylhydrazine can have another acetyl group added to it by arylamine N-acetyltransferase 2 to form diacetylhydrazine which is then excreted. It can alternatively be processed by cytochrome P450 2E1 into hepatotoxins, which are then joined to glutatione by glutatione S-transferase omega-2 to form R-S-glutatione, which is then excreted. Finally, isonicotinic acid can react with a glycine in an unclear reaction, potentially requiring ATP and coenzyme A and forming an intermediate, producing isonicotinylglycine, which is also excreted.
References
Isoniazid Metabolism References
Argyrou A, Vetting MW, Blanchard JS: New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP. J Am Chem Soc. 2007 Aug 8;129(31):9582-3. doi: 10.1021/ja073160k. Epub 2007 Jul 18.
Pubmed: 17636923
Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC: Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science. 1998 Jan 2;279(5347):98-102.
Pubmed: 9417034
Nguyen M, Quemard A, Broussy S, Bernadou J, Meunier B: Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2002 Jul;46(7):2137-44.
Pubmed: 12069966
Forbes LV, Furtmuller PG, Khalilova I, Turner R, Obinger C, Kettle AJ: Isoniazid as a substrate and inhibitor of myeloperoxidase: identification of amine adducts and the influence of superoxide dismutase on their formation. Biochem Pharmacol. 2012 Oct 1;84(7):949-60. doi: 10.1016/j.bcp.2012.07.020. Epub 2012 Jul 27.
Pubmed: 22846601
Khan SR, Morgan AG, Michail K, Srivastava N, Whittal RM, Aljuhani N, Siraki AG: Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD(+) adduct formation: A comparison of the reactivity of isoniazid with its known human metabolites. Biochem Pharmacol. 2016 Apr 15;106:46-55. doi: 10.1016/j.bcp.2016.02.003. Epub 2016 Feb 9.
Pubmed: 26867495
Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM, Elwood K, Marra F, Brooks-Wilson A: Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J. 2010 Dec;10(6):524-36. doi: 10.1038/tpj.2010.5. Epub 2010 Mar 2.
Pubmed: 20195289
Klein DJ, Boukouvala S, McDonagh EM, Shuldiner SR, Laurieri N, Thorn CF, Altman RB, Klein TE: PharmGKB summary: isoniazid pathway, pharmacokinetics. Pharmacogenet Genomics. 2016 Sep;26(9):436-44. doi: 10.1097/FPC.0000000000000232.
Pubmed: 27232112
Wang P, Pradhan K, Zhong XB, Ma X: Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016 Sep;6(5):384-392. doi: 10.1016/j.apsb.2016.07.014. Epub 2016 Aug 3.
Pubmed: 27709007
Kita T, Tanigawara Y, Chikazawa S, Hatanaka H, Sakaeda T, Komada F, Iwakawa S, Okumura K: N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull. 2001 May;24(5):544-9.
Pubmed: 11379777
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings